Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 08, 2019

SELL
$11.19 - $18.56 $418,315 - $693,828
-37,383 Closed
0 $0
Q3 2018

Nov 09, 2018

BUY
$16.05 - $16.87 $599,997 - $630,651
37,383 New
37,383 $631,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.15B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Dc Investments Management, LLC Portfolio

Follow Dc Investments Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dc Investments Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dc Investments Management, LLC with notifications on news.